Affimed N.V.

-0.01 (-2.41%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)67.33M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.08 Million
Adjusted EPS-$0.20
See more estimates
10-Day MA$0.48
50-Day MA$0.54
200-Day MA$0.83
See more pivots

Affimed N.V. Stock, NASDAQ:AFMD

Technologiepark, Im Neuenheimer Feld 582, Heidelberg, Baden Wuerttemberg 69120
Phone: +49.6221.6743.60
Number of Employees: 228


Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company�s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.